Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Beejal Amin

Neurological Surgery Oak Lawn, IL Medical Doctor

NPI 1275742983 CMS profile 457475

4400 W 95Th St Ste 407, Oak Lawn, IL 60453

Open in the dashboard

General payments

$22,735

69 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Beejal Amin of Oak Lawn, IL is reported in the CMS Open Payments database as having received $22,735 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $55 1
2024 General $1,270 3
2023 General $5,587 27
2022 General $3,115 12
2021 General $11,325 10
2020 General $991 6
2019 General $393 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Beejal Amin
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Beejal Amin were reported at $55. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Beejal Amin Neurological Surgery median Middle half National median
2019 $393 $582 $138–$3,006 $163
2020 $991 $294 $76–$2,174 $114
2021 $11,325 $387 $105–$2,432 $132
2022 $3,115 $542 $139–$2,989 $149
2023 $5,587 $534 $145–$2,697 $160
2024 $1,270 $574 $155–$3,046 $164
2025 $55 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. MiRus, LLC $13,220 10 payments
  2. CTL Medical Corporation $4,200 3 payments
  3. NuVasive, Inc. $1,987 14 payments
  4. Medical Device Business Services, Inc. $1,170 1 payment
  5. Ethicon Inc. $878 1 payment
  6. DePuy Synthes Sales Inc. $488 17 payments
  7. Stryker Corporation $321 11 payments
  8. Abbott Laboratories $128 1 payment
  9. Providence Medical Technology, Inc. $91 1 payment
  10. Globus Medical, Inc. $73 2 payments
  11. Other $181 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $18,248 10 payments
  2. Travel and Lodging $2,671 10 payments
  3. Food and Beverage $1,817 49 payments
Products named General payments · program years 2019–2025
  1. EUROPA Pedicle Screw System $13,220 10 payments
  2. CYGNUS Anterior Cervical Plate $13,220 10 payments
  3. IO Expandable Lumbar Interbody $13,220 10 payments
  4. Spinal $4,200 3 payments
  5. Pulse $1,948 12 payments
  6. RIGEL 3DR Cervical Interbody $1,750 3 payments
  7. MiRus 3DR Lumbar Interbody System $1,750 3 payments
  8. MOUNTAINEER $1,170 1 payment
  9. SYNAPSE $1,170 1 payment
  10. Expedium VERSE $149 5 payments
  11. Other $1,647 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

51

Median for Neurosurgery: 83

Drug cost

$467

Median for Neurosurgery: $872

Branded share of claims

41.2%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 21 $241
Cyclobenzaprine Hcl Generic 14 $135
Gabapentin Generic 16 $92

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$124,450

Medicare's payments for the services billed

Medicare patients

275

Average age 74

Services billed

542

163 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Diabetes 33%
Depression 32%
Chronic kidney disease 28%
Osteoporosis 25%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record